{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001952","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.531542+00:00","generated_at":"2026-05-16T11:15:15.560640+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Century Therapeutics raises $135M in oversubscribed private placement to fund CNTY-813 T1D program","bullets":["Gross proceeds ~$135M; 117.4M shares/pre-funded warrants + 58.7M warrants at $1.15 per unit.","Led by new investor TCGX; includes RA Capital, Commodore, Deep Track, RTW, Venrock, T1D Fund.","Proceeds fund lead candidate CNTY-813 (beta islet cell for T1D); cash runway extended to Q1 2029.","IND submission for CNTY-813 expected in 2026; initial clinical data anticipated in 2027.","Full exercise of warrants could yield additional ~$153M at $2.60 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001952","json":"https://secwatch.observer/filing/0001104659-26-001952.json","markdown":"https://secwatch.observer/filing/0001104659-26-001952.md","text":"https://secwatch.observer/filing/0001104659-26-001952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/0001104659-26-001952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:15:15.560640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebfc119fea8a1bf7ea4c1b05864d8534c94a27db","claim":"Century Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $135.0 million (effective 2026-01-07).","evidence_excerpt":"On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and/or, (ii) pre-funded warrants to purchase 25,360,704 shares of Common Stock (“Pre-Funded Warrants”) and (b) warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants in lieu thereof (“Common Warrants”, together with the Pre-Funded Warrants, the “Warrants”) at a purchase price of $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant and a purchase price of $1.1499 per Pre-Funded Warrant and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant (the “Private Placemen","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/0001104659-26-001952-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"approximately $135.0 million"},{"label":"Effective","value":"2026-01-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}